Hormone Replacement Therapy Market
Hormone Replacement Therapy Market Analysis by Estrogen Hormone Replacement Therapy, Thyroid Replacement Therapy, and Growth Hormone Replacement Therapy from 2023 to 2033
Analysis of Hormone Replacement Therapy Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Hormone Replacement Therapy (HRT) Market Outlook (2023 to 2033)
The global hormone replacement therapy market size is projected to increase from a value of US$ 22.5 billion in 2023 to US$ 43.7 billion by the end of 2033, expanding at a CAGR of 6.8% through the study period of 2023 to 2033.
Hormone replacement therapy is used to treat issues such as menopause, osteoporosis, thyroid, dementia, etc. An increase in the incidence of these diseases is projected to boost demand for hormone replacement therapy in the long run. The growing awareness regarding the benefits of hormone replacement therapy for menopausal symptoms is forecasted to be a common driver for hormone replacement industry growth across the world.
Expanding geriatric population, rising number of menopausal women, increasing availability of favourable reimbursement policies for hormone replacement procedures, growing availability of novel hormone replacement medications, and rising popularity of customized hormone replacement therapies for different chronic diseases are other influential aspects driving hormone replacement therapy demand from 2023 to 2033. Bio-identical hormone replacement therapy is anticipated to gain massive popularity by the end of the study period.
- In April 2023, a new HRT prescription prepayment certificate (PPC) was launched through the NHS England National Menopause Care Improvement Programme. This initiative was expected to help around 400,000 women in the country.
The risk of cancerous cell development in the use of combination hormone replacement therapies is estimated to be a major obstacle inhibiting HRT providers from reaching their full growth potential. Demand for low-cost generic versions of hormone replacement drugs is predicted to surge at a rapid pace over the next ten years and offer highly remunerative opportunities for incoming as well as established hormone replacement therapy product manufacturers.
| Report Attributes | Details |
|---|---|
|
Hormone Replacement Therapy Market Size (2023) |
US$ 22.5 Billion |
|
Projected Market Value (2033F) |
US$ 43.7 Billion |
|
Global Market Growth Rate (2023 to 2033) |
6.8% CAGR |
|
North America Market Share (2023) |
25% |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How Can Start-ups Benefit in the Global HRT Market?
“Menopausal Women – Gold Mine of Opportunity for Hormone Replacement Therapy Providers”
Menopause has emerged as a key area of focus for hormone replacement therapy providers as it has been a neglected topic in the healthcare industry for years. The absence of proper menopause care and solutions to help manage menopause effectively makes it an important topic for hormone replacement product vendors in the future as several women move into the menopausal stage, the result of a rapidly aging world population.
Incoming hormone replacement therapy companies are focusing on raising new capital to fund their R&D efforts and promote product innovation that allows them to stand out from the global competition.
- In March 2022, Vira Health, a United Kingdom-based company focused on providing personalized digital therapeutics for menopausal women, announced that it has raised US$ 12 million from Octopus Ventures and participation from other investors as well. The company has plans of using the raised capital to advance its personalized menopause support offerings for women.
- In April 2022, Evernow, a telehealth start-up focusing on women’s health and founded 2019, announced that it had raised US$ 28.5 million in a Series A funding round. The company intended to utilize the capital to finance its efforts to provide virtual menopause treatment, hormone therapies, and other services with round-the-clock support.
Learning more about factors such as local supply, pricing trends, product standards, safety regulations, and new developments from this hormone replacement therapy industry study by skilled analysts at Fact.MR, a market research and competitive intelligence provider, could help start-ups scale their business and cash in on new opportunities the market has to offer.
What is the Major Obstacle to Hormone Replacement Business Success?
“Carcinogenic Effects of Combination Hormone Replacement Therapies”
Use of hormone replacement therapy can lead to cancerous cell development. The use of combination hormone replacement therapy (combination of progesterone and estrogen) can increase the risk of breast cancer by 75 percent even if used for a short timeframe, some studies suggest.
- According to the U.S Women’s Health Initiative, the use of combination hormone replacement therapy comes with the risk of development of several cancers including ovarian cancer and uterus cancers.
This aspect is expected to confine the growth in the adoption of hormone replacement therapy in the forthcoming years. Other hormone replacement therapy-related disorders such as stroke, cardiac disorders, and blood clots are further expected to negatively impact the hormone replacement therapy market growth.
Leading companies in the hormone replacement therapy market are concentrating on expanding their current product portfolio. New hormone replacement therapy formulations being the core focus, companies are carrying out trials and gaining FDA approvals. Private equity firms are focused on acquiring emerging participants that are involved in drug delivery systems in the hormone replacement therapy space.
Country-wise Insights
Why Should Hormone Replacement Therapy Companies Target Canada?
“Rising Awareness Regarding Hormone Replacement Therapy Benefits”
With North America accounting for 25% share of the global hormone replacement therapy market, besides the United States, Canada is also expected to be a key player in this market.
Canada is an emerging space for all types of healthcare solutions and services owing to the increasing number of geriatric people and expanding population that is driven by its PR visa initiatives. The government of the country is investing heavily in healthcare infrastructure development and launching initiatives to promote awareness regarding the benefits associated with hormone replacement therapies.
- Use of hormone replacement therapies to treat menopausal symptoms in women has been approved by Health Canada, the government body of Canada responsible for the country’s health policies.
Increasing number of clinical trials being carried out to explore the effects of hormone replacement therapy products on different disease conditions are also anticipated to uplift hormone replacement therapy demand in Canada over the next ten years.
Which Asian Countries are Investment-worthy Market in This Space?
“Japan, China, India – Key Countries Attracting Hormone Replacement Therapy Providers”
Demand for hormone replacement therapy in Japan is poised to dominate the Asia Pacific regional marketplace through 2033 and this can primarily be attributed to the presence of high senescent population in the country. The growing use of HRT products to treat osteoporosis, dementia, and other old age-related disorders is forecasted to make Japan a highly opportune space for hormone replacement therapy companies through 2033.
Supportive government initiatives to advance healthcare infrastructure and the growing availability of novel drug delivery solutions are also offering attractive growth scope for hormone replacement therapy companies in countries such as China, India, and Indonesia in the future. Surging awareness regarding menopause and the benefits of hormone therapies to treat the same are also slated to boost sales of hormone replacement therapy products in the aforementioned countries across the study period.
Where Do Hormone Replacement Therapy Companies Find Sanctuary in Europe?
“United Kingdom to Offer Lucrative Moneymaking Opportunities”
Women in the United Kingdom are becoming more aware of menopausal symptoms and taking steps to alleviate these symptoms through the use of hormone replacement therapies. Multiple supportive government initiatives have been promoting the use of hormone replacement products in the country and this is also slated to open up new avenues of opportunities for upcoming as well as new hormone replacement therapy providers.
- As per the National Institute for Health and Care Excellence (Nice), around 1 million women in the United Kingdom use HRT treatment to alleviate the symptoms of menopause.
- In 2022, the United Kingdom experienced shortages in the supply of multiple HRT medications such as Oestrogel, FemSeven Sequi Patches, etc. The shortages were attributed to limited supply and rising demand for hormone replacement therapy products.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Which Therapy is the Most Profitable for HRT Companies?
“Demand for Estrogen Hormone Replacement Therapies Generating Most Revenue”
Based on therapy type, the hormone replacement therapy market is segmented into estrogen hormone replacement therapy, thyroid replacement therapy, and growth hormone replacement therapy.
Awareness regarding menopause and postmenopausal issues has been increasing among women around the world and this is projected to be the prime factor boosting sales of estrogen hormone replacement products going forward. The average onset age of menopause in women is 50 and the rapidly expanding geriatric population of the world is influentially pushing several women in this category and promoting demand for estrogen hormone replacement therapies.
Competitive Landscape
Leading hormone replacement therapy companies are focusing efforts and strategies that allow them to scale their market presence and improve revenue generation capacity. Mergers, acquisitions, and product launches are some of the most preferred and used tactics by established as well as new hormone replacement therapy providers.
- In March 2022, Pfizer Inc., a leading name in the hormone replacement therapy market landscape, announced that it had completed the acquisition of Arena Pharmaceuticals, a clinical-stage biotech company based in the United States. Pfizer expanded its therapy offerings through this acquisition and bolstered its market share in the global competitive landscape.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of Hormone Replacement Therapy Industry Research
-
By Therapy Type :
- Estrogen Hormone Replacement Therapy
- Thyroid Replacement Therapy
- Growth Hormone Replacement Therapy
-
By Dosage Form :
- Tablets
- Patches
- Injections
- Implants
- Creams
- Others
-
By Indication :
- Menopause
- Osteoporosis
- Thyroid
- Growth Hormone Deficiency
-
By Sales Channel :
- Hospital Pharmacies
- Clinics
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Executive Summary 1.1. Key Findings 1.1.1. Overall Market 1.1.2. Segment Overview 1.1.3. Regional Overview 1.1.4. Competitor’s Focus 1.1.5. Consumer’s Perception 1.2. Summary of Statistics 1.3. Market Characteristics and Attributes 2. Market Overview 2.1. Introduction and Definition 2.2. Research Scope 3. COVID 19 Impact Assessment 3.1. Demand in Market 3.1.1. Global Market Quarterly Market Value Analysis (US$ Mn), 2022 3.1.2. Global Market Value Y-o-Y Growth Pre and Post Crisis Projection 3.1.3. Global Market Recalibrated Growth Projection (US$ Mn) 3.2. Market Shrink and Recovery Trend Assessment, by Region 3.3. Market Recalibrated Market and Growth Assessment, by Region 4. Market Background 4.1. Country wise Market Attractiveness Index 4.2. Market Scenario-based Forecast 4.3. Value Chain Analysis 4.3.1. List of Manufacturers 4.3.2. List of Online Retailers 4.3.3. List of Sales Channels 4.4. Investment Feasibility Assessment 4.4.1. Investment Feasibility for Market 4.5. Porter’s Five Forces Analysis 4.5.1. Bargaining Power of Buyers 4.5.2. Bargaining Power of Suppliers 4.5.3. Threat of Substitute Dosage Forms 4.5.4. Threat of New Entrants 4.5.5. Intensity of Rivalry 4.5.6. 5 Forces Acting Upon Market 4.6. PESTEL Analysis 4.7. Forecast Factors 4.7.1. Increasing Government Regulations 4.7.2. Expansion of Industry 4.7.3. Compliance to Insurance Regulations 4.7.4. Advancements in Market 4.7.5. Increasing Global Temperature 4.7.6. Technological Advancements 4.8. Market Dynamics 4.8.1. Market Drivers 4.8.2. Market Restraints 4.8.3. Opportunity Windows 4.8.4. Key Trends 5. Global Market Pricing Analysis 5.1. Price Point Assessment 5.1.1. Weighted Average Pricing (2022), by Region 5.1.2. Key Factors Influencing Pricing 5.1.3. Price Benchmark by Region 5.1.4. Price Benchmark by Therapy Type 6. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033) 6.1. Market Overview 6.2. Introduction to Market Statistics 6.2.1. Global Market Value (US$ Mn) 6.2.2. Global Cumulative Historical Market and Absolute $ Opportunity 6.3. Y-o-Y Growth and Incremental Opportunity 6.4. Absolute Dollar Historical Market and Absolute Dollar Opportunity 7. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Therapy Type 7.1. Introduction 7.1.1. Type Definition 7.1.1.1. Estrogen Hormone Replacement Therapy 7.1.1.2. Thyroid Replacement Therapy 7.1.1.3. Growth Hormone Replacement Therapy 7.1.2. Market Key Findings, by Therapy Type 7.1.2.1. Absolute $ Opportunity (2023 to 2033) 7.1.2.2. Market Share and BPS Analysis 7.1.2.3. Y-o-Y Growth Projections 7.1.2.4. Market Attractiveness Analysis 7.2. Global Market Regional Market Share Comparison, by Therapy Type 8. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Dosage Form 8.1. Introduction 8.1.1. Dosage Form Definition 8.1.1.1. Tablets 8.1.1.2. Patches 8.1.1.3. Injections 8.1.1.4. Implants 8.1.1.5. Creams 8.1.1.6. Others 8.1.2. Market Key Findings, by Dosage Form 8.1.2.1. Absolute $ Opportunity (2023 to 2033) 8.1.2.2. Market Share and BPS Analysis 8.1.2.3. Y-o-Y Growth Projections 8.1.2.4. Market Attractiveness Analysis 8.2. Global Market Regional Market Share Comparison, by Dosage Form 9. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Indication 9.1. Introduction 9.1.1. Indication Definition 9.1.1.1. Menopause 9.1.1.2. Osteoporosis 9.1.1.3. Thyroid 9.1.1.4. Growth Hormone Deficiency 9.1.2. Market Key Findings, by Indication 9.1.2.1. Absolute $ Opportunity (2023 to 2033) 9.1.2.2. Market Share and BPS Analysis 9.1.2.3. Y-o-Y Growth Projections 9.1.2.4. Market Attractiveness Analysis 9.2. Global Market Regional Market Share Comparison, by Indication 10. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Sales Channel 10.1. Introduction 10.1.1. Sales Channel Definition 10.1.1.1. Hospital Pharmacies 10.1.1.2. Clinics 10.1.1.3. Retail Pharmacies 10.1.1.4. Online Pharmacies 10.1.2. Market Key Findings, by Sales Channel 10.1.2.1. Absolute $ Opportunity (2023 to 2033) 10.1.2.2. Market Share and BPS Analysis 10.1.2.3. Y-o-Y Growth Projections 10.1.2.4. Market Attractiveness Analysis 10.2. Global Market Regional Market Share Comparison, by Sales Channel 11. Global Market Analysis (2018 to 2022) and Forecast (2023 to 2033), by Region 11.1. Introduction 11.1.1. Regional Coverage 11.1.1.1. North America 11.1.1.2. Europe 11.1.1.3. East Asia 11.1.1.4. South Asia 11.1.1.5. Latin America 11.1.1.6. Middle East & Africa (MEA) 11.1.1.7. Oceania 11.1.2. Market Key Findings, by Region 11.1.2.1. Absolute $ Opportunity (2023 to 2033) 11.1.2.2. Market Share and BPS Analysis 11.1.2.3. Y-o-Y Growth Projections 11.1.2.4. Market Attractiveness Analysis 11.2. Global Market Regional Market Share Comparison, by Region 12. North America Market Analysis and Forecast 12.1. Overview 12.1.1. North America Share in Global Market 12.2. Market Value & Volume Forecast and Analysis 12.2.1. By Country 12.2.1.1. United States 12.2.1.2. Canada 12.2.2. By Therapy Type 12.2.3. By Dosage Form 12.2.4. By Indication 12.2.5. By Sales Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.1.1. United States 12.3.1.2. Canada 12.3.2. By Therapy Type 12.3.3. By Dosage Form 12.3.4. By Indication 12.3.5. By Sales Channel 12.4. Y-o-Y Growth Comparison 13. Europe Market Analysis and Forecast 13.1. Overview 13.1.1. Europe Share in Global Market 13.2. Market Value & Volume Forecast and Analysis 13.2.1. By Country 13.2.1.1. Germany 13.2.1.2. United Kingdom 13.2.1.3. France 13.2.1.4. Russia 13.2.1.5. Spain 13.2.1.6. Italy 13.2.1.7. Rest of Europe 13.2.2. By Therapy Type 13.2.3. By Dosage Form 13.2.4. By Indication 13.2.5. By Sales Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. United Kingdom 13.3.1.3. France 13.3.1.4. Russia 13.3.1.5. Spain 13.3.1.6. Italy 13.3.1.7. Rest of Europe 13.3.2. By Therapy Type 13.3.3. By Dosage Form 13.3.4. By Indication 13.3.5. By Sales Channel 13.4. Y-o-Y Growth Comparison 14. East Asia Market Analysis and Forecast 14.1. Overview 14.1.1. East Asia Share in Global Market 14.2. Market Value & Volume Forecast and Analysis 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Therapy Type 14.2.3. By Dosage Form 14.2.4. By Indication 14.2.5. By Sales Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Therapy Type 14.3.3. By Dosage Form 14.3.4. By Indication 14.3.5. By Sales Channel 14.4. Y-o-Y Growth Comparison 15. South Asia Market Analysis and Forecast 15.1. Overview 15.1.1. South Asia Share in Global Market 15.2. Market Value & Volume Forecast and Analysis 15.2.1. By Country 15.2.1.1. India 15.2.1.2. Singapore 15.2.1.3. Indonesia 15.2.1.4. Thailand 15.2.1.5. Rest of South Asia 15.2.2. By Therapy Type 15.2.3. By Dosage Form 15.2.4. By Indication 15.2.5. By Sales Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Singapore 15.3.1.3. Indonesia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Therapy Type 15.3.3. By Dosage Form 15.3.4. By Indication 15.3.5. By Sales Channel 15.4. Y-o-Y Growth Comparison 16. Latin America Market Analysis and Forecast 16.1. Overview 16.1.1. Latin America Share in Global Market 16.2. Market Value & Volume Forecast and Analysis 16.2.1. By Country 16.2.1.1. Brazil 16.2.1.2. Mexico 16.2.1.3. Rest of LATAM 16.2.2. By Therapy Type 16.2.3. By Dosage Form 16.2.4. By Indication 16.2.5. By Sales Channel 16.3. Market Attractiveness Analysis 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Rest of LATAM 16.3.2. By Therapy Type 16.3.3. By Dosage Form 16.3.4. By Indication 16.3.5. By Sales Channel 16.4. Y-o-Y Growth Comparison 17. Middle East & Africa Market Analysis and Forecast 17.1. Overview 17.1.1. Middle East & Africa Share in Global Market 17.2. Market Value & Volume Forecast and Analysis 17.2.1. By Country 17.2.1.1. Turkey 17.2.1.2. GCC Countries 17.2.1.3. Rest of MEA 17.2.2. By Therapy Type 17.2.3. By Dosage Form 17.2.4. By Indication 17.2.5. By Sales Channel 17.3. Market Attractiveness Analysis 17.3.1. By Country 17.3.1.1. Turkey 17.3.1.2. GCC Countries 17.3.1.3. Rest of MEA 17.3.2. By Therapy Type 17.3.3. By Dosage Form 17.3.4. By Indication 17.3.5. By Sales Channel 17.4. Y-o-Y Growth Comparison 18. Oceania Market Analysis and Forecast 18.1. Overview 18.1.1. Oceania Share in Global Market 18.2. Market Value & Volume Forecast and Analysis 18.2.1. By Country 18.2.1.1. Australia 18.2.1.2. New Zealand 18.2.2. By Therapy Type 18.2.3. By Dosage Form 18.2.4. By Indication 18.2.5. By Sales Channel 18.3. Market Attractiveness Analysis 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Therapy Type 18.3.3. By Dosage Form 18.3.4. By Indication 18.3.5. By Sales Channel 18.4. Y-o-Y Growth Comparison 19. Global Market Analysis Key Countries 19.1. United States 19.1.1. Share of North American Market 19.1.2. Market Share, by Therapy Type, 2022 19.1.3. Market Share, by Dosage Form, 2022 19.1.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.1.5. Market Share, by Sales Channel, 2022 19.2. Canada 19.2.1. Share of North American Market 19.2.2. Market Share, by Therapy Type, 2022 19.2.3. Market Share, by Dosage Form, 2022 19.2.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.2.5. Market Share, by Sales Channel, 2022 19.3. Germany 19.3.1. Share of European Market 19.3.2. Market Share, by Therapy Type, 2022 19.3.3. Market Share, by Dosage Form, 2022 19.3.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.3.5. Market Share, by Sales Channel, 2022 19.4. United Kingdom 19.4.1. Share of European Market 19.4.2. Market Share, by Therapy Type, 2022 19.4.3. Market Share, by Dosage Form, 2022 19.4.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.4.5. Market Share, by Sales Channel, 2022 19.5. France 19.5.1. Share of European Market 19.5.2. Market Share, by Therapy Type, 2022 19.5.3. Market Share, by Dosage Form, 2022 19.5.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.5.5. Market Share, by Sales Channel, 2022 19.6. Russia 19.6.1. Share of European Market 19.6.2. Market Share, by Therapy Type, 2022 19.6.3. Market Share, by Dosage Form, 2022 19.6.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.6.5. Market Share, by Sales Channel, 2022 19.7. Spain 19.7.1. Share of European Market 19.7.2. Market Share, by Therapy Type, 2022 19.7.3. Market Share, by Dosage Form, 2022 19.7.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.7.5. Market Share, by Sales Channel, 2022 19.8. Italy 19.8.1. Share of European Market 19.8.2. Market Share, by Therapy Type, 2022 19.8.3. Market Share, by Dosage Form, 2022 19.8.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.8.5. Market Share, by Sales Channel, 2022 19.9. China 19.9.1. Share of East Asian Market 19.9.2. Market Share, by Therapy Type, 2022 19.9.3. Market Share, by Dosage Form, 2022 19.9.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.9.5. Market Share, by Sales Channel, 2022 19.10. Japan 19.10.1. Share of East Asian Market 19.10.2. Market Share, by Therapy Type, 2022 19.10.3. Market Share, by Dosage Form, 2022 19.10.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.10.5. Market Share, by Sales Channel, 2022 19.11. South Korea 19.11.1. Share of East Asian Market 19.11.2. Market Share, by Therapy Type, 2022 19.11.3. Market Share, by Dosage Form, 2022 19.11.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.11.5. Market Share, by Sales Channel, 2022 19.12. India 19.12.1. Share of South Asian Market 19.12.2. Market Share, by Therapy Type, 2022 19.12.3. Market Share, by Dosage Form, 2022 19.12.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.12.5. Market Share, by Sales Channel, 2022 19.13. Singapore 19.13.1. Share of South Asian Market 19.13.2. Market Share, by Therapy Type, 2022 19.13.3. Market Share, by Dosage Form, 2022 19.13.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.13.5. Market Share, by Sales Channel, 2022 19.14. Indonesia 19.14.1. Share of South Asian Market 19.14.2. Market Share, by Therapy Type, 2022 19.14.3. Market Share, by Dosage Form, 2022 19.14.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.14.5. Market Share, by Sales Channel, 2022 19.15. Thailand 19.15.1. Share of South Asian Market 19.15.2. Market Share, by Therapy Type, 2022 19.15.3. Market Share, by Dosage Form, 2022 19.15.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.15.5. Market Share, by Sales Channel, 2022 19.16. Brazil 19.16.1. Share of Latin American Market 19.16.2. Market Share, by Therapy Type, 2022 19.16.3. Market Share, by Dosage Form, 2022 19.16.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.16.5. Market Share, by Sales Channel, 2022 19.17. Mexico 19.17.1. Share of Latin American Market 19.17.2. Market Share, by Therapy Type, 2022 19.17.3. Market Share, by Dosage Form, 2022 19.17.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.17.5. Market Share, by Sales Channel, 2022 19.18. Turkey 19.18.1. Share of MEA Market 19.18.2. Market Share, by Therapy Type, 2022 19.18.3. Market Share, by Dosage Form, 2022 19.18.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.18.5. Market Share, by Sales Channel, 2022 19.19. GCC Countries 19.19.1. Share of MEA Market 19.19.2. Market Share, by Therapy Type, 2022 19.19.3. Market Share, by Dosage Form, 2022 19.19.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.19.5. Market Share, by Sales Channel, 2022 19.20. South Africa 19.20.1. Share of MEA Market 19.20.2. Market Share, by Therapy Type, 2022 19.20.3. Market Share, by Dosage Form, 2022 19.20.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.20.5. Market Share, by Sales Channel, 2022 19.21. Australia 19.21.1. Share of Oceania Market 19.21.2. Market Share, by Therapy Type, 2022 19.21.3. Market Share, by Dosage Form, 2022 19.21.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.21.5. Market Share, by Sales Channel, 2022 19.22. New Zealand 19.22.1. Share of Oceania Market 19.22.2. Market Share, by Therapy Type, 2022 19.22.3. Market Share, by Dosage Form, 2022 19.22.4. Market Value (US$ Mn) and Forecast 2023 to 2033 19.22.5. Market Share, by Sales Channel, 2022 20. Competition Landscape 20.1. Global Market Competition Dashboard 20.2. Global Market Tier Structure 20.2.1. Market Structure in 2022 20.2.2. Anticipated Market Structure in 2033 20.3. Global Market Share Analysis 21. Competition Analysis 21.1. Novo Nordisk A/S 21.1.1. Company Overview 21.1.2. Dosage Form Portfolio 21.1.3. Key Strategies 21.1.4. Regional Presence 21.1.5. Key Developments 21.1.6. SWOT Analysis 21.2. Bayer AG 21.2.1. Company Overview 21.2.2. Dosage Form Portfolio 21.2.3. Key Strategies 21.2.4. Regional Presence 21.2.5. Key Developments 21.2.6. SWOT Analysis 21.3. Endo International Plc 21.3.1. Company Overview 21.3.2. Dosage Form Portfolio 21.3.3. Key Strategies 21.3.4. Regional Presence 21.3.5. Key Developments 21.3.6. SWOT Analysis 21.4. Janssen NV 21.4.1. Company Overview 21.4.2. Dosage Form Portfolio 21.4.3. Key Strategies 21.4.4. Regional Presence 21.4.5. Key Developments 21.4.6. SWOT Analysis 21.5. Mithra Pharmaceuticals 21.5.1. Company Overview 21.5.2. Dosage Form Portfolio 21.5.3. Key Strategies 21.5.4. Regional Presence 21.5.5. Key Developments 21.5.6. SWOT Analysis 21.6. Novartis AG 21.6.1. Company Overview 21.6.2. Dosage Form Portfolio 21.6.3. Key Strategies 21.6.4. Regional Presence 21.6.5. Key Developments 21.6.6. SWOT Analysis 21.7. Pfizer Inc. 21.7.1. Company Overview 21.7.2. Dosage Form Portfolio 21.7.3. Key Strategies 21.7.4. Regional Presence 21.7.5. Key Developments 21.7.6. SWOT Analysis 21.8. Allergen Plc 21.8.1. Company Overview 21.8.2. Dosage Form Portfolio 21.8.3. Key Strategies 21.8.4. Regional Presence 21.8.5. Key Developments 21.8.6. SWOT Analysis 21.9. Merck KGaA 21.9.1. Company Overview 21.9.2. Dosage Form Portfolio 21.9.3. Key Strategies 21.9.4. Regional Presence 21.9.5. Key Developments 21.9.6. SWOT Analysis 21.10. Teva Pharmaceuticals 21.10.1. Company Overview 21.10.2. Dosage Form Portfolio 21.10.3. Key Strategies 21.10.4. Regional Presence 21.10.5. Key Developments 21.10.6. SWOT Analysis 21.11. Mylan N.V. 21.11.1. Company Overview 21.11.2. Dosage Form Portfolio 21.11.3. Key Strategies 21.11.4. Regional Presence 21.11.5. Key Developments 21.11.6. SWOT Analysis 22. Appendix 23. Definitions of Analytical Frameworks 24. Sources and References
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market by Therapy Type, 2018 to 2033
Table 02: Global Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 03: Global Market by Dosage Form, 2018 to 2033
Table 04: Global Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 05: Global Market by Indication, 2018 to 2033
Table 06: Global Market Value (US$ Mn), by Indication, 2018 to 2033
Table 07: Global Market by Sales Channel, 2018 to 2033
Table 08: Global Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 09: Global Market by Region, 2018 to 2033
Table 10: Global Market Value (US$ Mn), by Region, 2018 to 2033
Table 11: North America Market by Therapy Type, 2018 to 2033
Table 12: North America Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 13: North America Market by Dosage Form, 2018 to 2033
Table 14: North America Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 15: North America Market by Indication, 2018 to 2033
Table 16: North America Market Value (US$ Mn), by Indication, 2018 to 2033
Table 17: North America Market by Sales Channel, 2018 to 2033
Table 18: North America Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 19: North America Market by Country, 2018 to 2033
Table 20: North America Market Value (US$ Mn), by Country, 2018 to 2033
Table 21: Europe Market by Therapy Type, 2018 to 2033
Table 22: Europe Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 23: Europe Market by Dosage Form, 2018 to 2033
Table 24: Europe Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 25: Europe Market by Indication, 2018 to 2033
Table 26: Europe Market Value (US$ Mn), by Indication, 2018 to 2033
Table 27: Europe Market by Sales Channel, 2018 to 2033
Table 28: Europe Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 29: Europe Market by Country, 2018 to 2033
Table 30: Europe Market Value (US$ Mn), by Country, 2018 to 2033
Table 31: East Asia Market by Therapy Type, 2018 to 2033
Table 32: East Asia Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 33: East Asia Market by Dosage Form, 2018 to 2033
Table 34: East Asia Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 35: East Asia Market by Indication, 2018 to 2033
Table 36: East Asia Market Value (US$ Mn), by Indication, 2018 to 2033
Table 37: East Asia Market by Sales Channel, 2018 to 2033
Table 38: East Asia Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 39: East Asia Market by Country, 2018 to 2033
Table 40: East Asia Market Value (US$ Mn), by Country, 2018 to 2033
Table 41: South Asia Market by Therapy Type, 2018 to 2033
Table 42: South Asia Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 43: South Asia Market by Dosage Form, 2018 to 2033
Table 44: South Asia Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 45: South Asia Market by Indication, 2018 to 2033
Table 46: South Asia Market Value (US$ Mn), by Indication, 2018 to 2033
Table 47: South Asia Market by Sales Channel, 2018 to 2033
Table 48: South Asia Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 49: South Asia Market by Country, 2018 to 2033
Table 50: South Asia Market Value (US$ Mn), by Country, 2018 to 2033
Table 51: Latin America Market by Therapy Type, 2018 to 2033
Table 52: Latin America Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 53: Latin America Market by Dosage Form, 2018 to 2033
Table 54: Latin America Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 55: Latin America Market by Indication, 2018 to 2033
Table 56: Latin America Market Value (US$ Mn), by Indication, 2018 to 2033
Table 57: Latin America Market by Sales Channel, 2018 to 2033
Table 58: Latin America Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 59: Latin America Market by Country, 2018 to 2033
Table 60: Latin America Market Value (US$ Mn), by Country, 2018 to 2033
Table 61: Middle East and Africa Market by Therapy Type, 2018 to 2033
Table 62: Middle East and Africa Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 63: Middle East and Africa Market by Dosage Form, 2018 to 2033
Table 64: Middle East and Africa Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 65: Middle East and Africa Market by Indication, 2018 to 2033
Table 66: Middle East and Africa Market Value (US$ Mn), by Indication, 2018 to 2033
Table 67: Middle East and Africa Market by Sales Channel, 2018 to 2033
Table 68: Middle East and Africa Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 69: Middle East and Africa Market by Country, 2018 to 2033
Table 70: Middle East and Africa Market Value (US$ Mn), by Country, 2018 to 2033
Table 71: Oceania Market by Therapy Type, 2018 to 2033
Table 72: Oceania Market Value (US$ Mn), by Therapy Type, 2018 to 2033
Table 73: Oceania Market by Dosage Form, 2018 to 2033
Table 74: Oceania Market Value (US$ Mn), by Dosage Form, 2018 to 2033
Table 75: Oceania Market by Indication, 2018 to 2033
Table 76: Oceania Market Value (US$ Mn), by Indication, 2018 to 2033
Table 77: Oceania Market by Sales Channel, 2018 to 2033
Table 78: Oceania Market Value (US$ Mn), by Sales Channel, 2018 to 2033
Table 79: Oceania Market by Country, 2018 to 2033
Table 80: Oceania Market Value (US$ Mn), by Country, 2018 to 2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Fig 01: Global Market Value (US$) and Y-o-Y Growth, 2018 to 2033
Fig 02: Global Absolute $ Historical Market (2018 to 2022) and Absolute $ Opportunity (2023 to 2033), US$ Mn
Fig 03: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Fig 04: Global Market Incremental $ Opportunity (US$ Thousand), 2023 to 2033
Fig 05: Global Market Share, By Therapy Type – 2023 to 2033
Fig 06: Global Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 07: Global Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 08: Global Market Share, By Dosage Form – 2023 to 2033
Fig 09: Global Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 10: Global Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 11: Global Market Share, By Indication – 2023 to 2033
Fig 12: Global Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 13: Global Market Attractiveness Index, By Indication – 2023 to 2033
Fig 14: Global Market Share, By Sales Channel – 2023 to 2033
Fig 15: Global Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 16: Global Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 17: Global Market Share, by Region – 2023 to 2033
Fig 18: Global Market Y-o-Y Growth Projections, by Region – 2023 to 2033
Fig 19: Global Market Attractiveness Index, by Region – 2023 to 2033
Fig 20: Y-o-Y Growth Comparison of Market: North America Vs North America Countries Vs North America Average
Fig 21: North America Market Share, By Therapy Type – 2023 to 2033
Fig 22: North America Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 23: North America Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 24: North America Market Share, By Dosage Form – 2023 to 2033
Fig 25: North America Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 26: North America Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 27: North America Market Share, By Indication – 2023 to 2033
Fig 28: North America Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 29: North America Market Attractiveness Index, By Indication – 2023 to 2033
Fig 30: North America Market Share, By Sales Channel – 2023 to 2033
Fig 31: North America Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 32: North America Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 33: North America Market Share, By Country – 2023 to 2033
Fig 34: North America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 35: North America Market Attractiveness Index, By Country – 2023 to 2033
Fig 36: Y-o-Y Growth Comparison of Market: Europe Vs Europe Countries Vs Europe Average
Fig 37: Europe Market Share, By Therapy Type – 2023 to 2033
Fig 38: Europe Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 39: Europe Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 40: Europe Market Share, By Dosage Form – 2023 to 2033
Fig 41: Europe Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 42: Europe Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 43: Europe Market Share, By Indication – 2023 to 2033
Fig 44: Europe Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 45: Europe Market Attractiveness Index, By Indication – 2023 to 2033
Fig 46: Europe Market Share, By Sales Channel – 2023 to 2033
Fig 47: Europe Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 48: Europe Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 49: Europe Market Share, By Country – 2023 to 2033
Fig 50: Europe Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 51: Europe Market Attractiveness Index, By Country – 2023 to 2033
Fig 52: Y-o-Y Growth Comparison of Market: East Asia Vs East Asia Countries Vs East Asia Average
Fig 53: East Asia Market Share, By Therapy Type – 2023 to 2033
Fig 54: East Asia Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 55: East Asia Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 56: East Asia Market Share, By Dosage Form – 2023 to 2033
Fig 57: East Asia Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 58: East Asia Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 59: East Asia Market Share, By Indication – 2023 to 2033
Fig 60: East Asia Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 61: East Asia Market Attractiveness Index, By Indication – 2023 to 2033
Fig 62: East Asia Market Share, By Sales Channel – 2023 to 2033
Fig 63: East Asia Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 64: East Asia Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 65: East Asia Market Share, By Country – 2023 to 2033
Fig 66: East Asia Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 67: East Asia Market Attractiveness Index, By Country – 2023 to 2033
Fig 68: Y-o-Y Growth Comparison of Market: South Asia Vs South Asia Countries Vs South Asia Average
Fig 69: South Asia Market Share, By Therapy Type – 2023 to 2033
Fig 70: South Asia Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 71: South Asia Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 72: South Asia Market Share, By Dosage Form – 2023 to 2033
Fig 73: South Asia Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 74: South Asia Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 75: South Asia Market Share, By Indication – 2023 to 2033
Fig 76: South Asia Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 77: South Asia Market Attractiveness Index, By Indication – 2023 to 2033
Fig 78: South Asia Market Share, By Sales Channel – 2023 to 2033
Fig 78: South Asia Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 80: South Asia Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 81: South Asia Market Share, By Country – 2023 to 2033
Fig 82: South Asia Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 83: South Asia Market Attractiveness Index, By Country – 2023 to 2033
Fig 84: Y-o-Y Growth Comparison of Market: Latin America Vs Latin America Countries Vs Latin America Average
Fig 85: Latin America Market Share, By Therapy Type – 2023 to 2033
Fig 86: Latin America Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 87: Latin America Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 88: Latin America Market Share, By Dosage Form – 2023 to 2033
Fig 89: Latin America Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 90: Latin America Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 91: Latin America Market Share, By Indication – 2023 to 2033
Fig 92: Latin America Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 93: Latin America Market Attractiveness Index, By Indication – 2023 to 2033
Fig 94: Latin America Market Share, By Sales Channel – 2023 to 2033
Fig 95: Latin America Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 96: Latin America Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 97: Latin America Market Share, By Country – 2023 to 2033
Fig 98: Latin America Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 99: Latin America Market Attractiveness Index, By Country – 2023 to 2033
Fig 100: Y-o-Y Growth Comparison of Market: MEA Vs MEA Countries Vs MEA Average
Fig 101: MEA Market Share, By Therapy Type – 2023 to 2033
Fig 102: MEA Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 103: MEA Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 104: MEA Market Share, By Dosage Form – 2023 to 2033
Fig 105: MEA Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 106: MEA Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 107: MEA Market Share, By Indication – 2023 to 2033
Fig 108: MEA Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 109: MEA Market Attractiveness Index, By Indication – 2023 to 2033
Fig 110: MEA Market Share, By Sales Channel – 2023 to 2033
Fig 111: MEA Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 112: MEA Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 113: MEA Market Share, By Country – 2023 to 2033
Fig 114: MEA Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 115: MEA Market Attractiveness Index, By Country – 2023 to 2033
Fig 116: Y-o-Y Growth Comparison of Market: Oceania Vs Oceania Countries Vs Oceania Average
Fig 117: Oceania Market Share, By Therapy Type – 2023 to 2033
Fig 118: Oceania Market Y-o-Y Growth Projections, By Therapy Type – 2023 to 2033
Fig 119: Oceania Market Attractiveness Index, By Therapy Type – 2023 to 2033
Fig 120: Oceania Market Share, By Dosage Form – 2023 to 2033
Fig 121: Oceania Market Y-o-Y Growth Projections, By Dosage Form – 2023 to 2033
Fig 122: Oceania Market Attractiveness Index, By Dosage Form – 2023 to 2033
Fig 123: Oceania Market Share, By Indication – 2023 to 2033
Fig 124: Oceania Market Y-o-Y Growth Projections, By Indication – 2023 to 2033
Fig 125: Oceania Market Attractiveness Index, By Indication – 2023 to 2033
Fig 126: Oceania Market Share, By Sales Channel – 2023 to 2033
Fig 127: Oceania Market Y-o-Y Growth Projections, By Sales Channel – 2023 to 2033
Fig 128: Oceania Market Attractiveness Index, By Sales Channel – 2023 to 2033
Fig 129: Oceania Market Share, By Country – 2023 to 2033
Fig 130: Oceania Market Y-o-Y Growth Projections, By Country – 2023 to 2033
Fig 131: Oceania Market Attractiveness Index, By Country – 2023 to 2033
Fig 132: United States Market share by Therapy Type, 2022
Fig 133: United States Market share by Dosage Form, 2022
Fig 134: United States Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 135: United States Market Share by Sales Channel, 2022
Fig 136: Canada Market share by Therapy Type, 2022
Fig 137: Canada Market share by Dosage Form, 2022
Fig 138: Canada Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 139: Canada Market Share by Sales Channel, 2022
Fig 140: Germany Market share by Therapy Type, 2022
Fig 141: Germany Market share by Dosage Form, 2022
Fig 142: Germany Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 143: Germany Market Share by Sales Channel, 2022
Fig 144: United Kingdom Market share by Therapy Type, 2022
Fig 145: United Kingdom Market share by Dosage Form, 2022
Fig 146: United Kingdom Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 147: United Kingdom Market Share by Sales Channel, 2022
Fig 148: France Market share by Therapy Type, 2022
Fig 149: France Market share by Dosage Form, 2022
Fig 150: France Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 151: France Market Share by Sales Channel, 2022
Fig 152: Russia Market share by Therapy Type, 2022
Fig 153: Russia Market share by Dosage Form, 2022
Fig 154: Russia Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 155: Russia Market Share by Sales Channel, 2022
Fig 156: Spain Market share by Therapy Type, 2022
Fig 157: Spain Market share by Dosage Form, 2022
Fig 158: Spain Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 159: Spain Market Share by Sales Channel, 2022
Fig 160: Italy Market share by Therapy Type, 2022
Fig 161: Italy Market share by Dosage Form, 2022
Fig 162: Italy Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 163: Italy Market Share by Sales Channel, 2022
Fig 164: China Market share by Therapy Type, 2022
Fig 165: China Market share by Dosage Form, 2022
Fig 166: China Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 167: China Market Share by Sales Channel, 2022
Fig 168: Japan Market share by Therapy Type, 2022
Fig 169: Japan Market share by Dosage Form, 2022
Fig 170: Japan Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 171: Japan Market Share by Sales Channel, 2022
Fig 172: South Korea Market share by Therapy Type, 2022
Fig 173: South Korea Market share by Dosage Form, 2022
Fig 174: South Korea Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 175: South Korea Market Share by Sales Channel, 2022
Fig 176: India Market share by Therapy Type, 2022
Fig 177: India Market share by Dosage Form, 2022
Fig 178: India Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 179: India Market Share by Sales Channel, 2022
Fig 180: Singapore Market share by Therapy Type, 2022
Fig 181: Singapore Market share by Dosage Form, 2022
Fig 182: Singapore Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 183: Singapore Market Share by Sales Channel, 2022
Fig 184: Indonesia Market share by Therapy Type, 2022
Fig 185: Indonesia Market share by Dosage Form, 2022
Fig 186: Indonesia Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 187: Indonesia Market Share by Sales Channel, 2022
Fig 188: Thailand Market share by Therapy Type, 2022
Fig 189: Thailand Market share by Dosage Form, 2022
Fig 190: Thailand Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 191: Thailand Market Share by Sales Channel, 2022
Fig 192: Brazil Market share by Therapy Type, 2022
Fig 193: Brazil Market share by Dosage Form, 2022
Fig 194: Brazil Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 195: Brazil Market Share by Sales Channel, 2022
Fig 196: Mexico Market share by Therapy Type, 2022
Fig 197: Mexico Market share by Dosage Form, 2022
Fig 198: Mexico Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 199: Mexico Market Share by Sales Channel, 2022
Fig 200: Turkey Market share by Therapy Type, 2022
Fig 201: Turkey Market share by Dosage Form, 2022
Fig 202: Turkey Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 203: Turkey Market Share by Sales Channel, 2022
Fig 204: GCC Countries Market share by Therapy Type, 2022
Fig 205: GCC Countries Market share by Dosage Form, 2022
Fig 206: GCC Countries Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 207: GCC Countries Market Share by Sales Channel, 2022
Fig 208: South Africa Market share by Therapy Type, 2022
Fig 209: South Africa Market share by Dosage Form, 2022
Fig 210: South Africa Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 211: South Africa Market Share by Sales Channel, 2022
Fig 212: Australia Market share by Therapy Type, 2022
Fig 213: Australia Market share by Dosage Form, 2022
Fig 214: Australia Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 215: Australia Market Share by Sales Channel, 2022
Fig 216: New Zealand Market share by Therapy Type, 2022
Fig 217: New Zealand Market share by Dosage Form, 2022
Fig 218: New Zealand Market Value (US$ Mn) and Forecast 2023 to 2033
Fig 219: New Zealand Market Share by Sales Channel, 2022
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the hormone replacement therapy market at present?
The global hormone replacement therapy market is valued at US$ 22.5 billion in 2023.
What is the future size of the hormone replacement therapy market?
By 2033-end, hormone replacement therapy demand is forecasted to reach a market value of US$ 43.7 billion.
How fast will hormone replacement therapy demand rise?
The market for hormone replacement therapy is set to expand at 6.8% CAGR from 2023 to 2033.
What is the most popular hormone therapy?
Estrogen replacement hormone therapy is the most popular type of hormone therapy.
Who are the renowned hormone replacement therapy providers?
Novo Nordisk A/S, Pfizer Inc., Endo International Plc, Allergen Plc, Janssen NV, and Novartis AG are key market players.
Which is the leading market for hormone replacement therapy companies?
Demand for hormone replacement therapies in North America accounts for around 25% of the global market share.
Hormone Replacement Therapy Market